CN116368243A - 复制应激通路剂组合物和用于治疗癌症的方法 - Google Patents

复制应激通路剂组合物和用于治疗癌症的方法 Download PDF

Info

Publication number
CN116368243A
CN116368243A CN202180069281.4A CN202180069281A CN116368243A CN 116368243 A CN116368243 A CN 116368243A CN 202180069281 A CN202180069281 A CN 202180069281A CN 116368243 A CN116368243 A CN 116368243A
Authority
CN
China
Prior art keywords
ecdna
tumor
cells
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180069281.4A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂安·哈西格
莱恩·汉森
斯内扎娜·米卢蒂诺维奇
杰森·克里斯蒂安森
扎迦利·霍恩比
苏希尔·乔杜里
安东尼·赛莱斯特
克利斯登·特纳
迪普提·威尔金森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boundless Bio Inc
Original Assignee
Boundless Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boundless Bio Inc filed Critical Boundless Bio Inc
Publication of CN116368243A publication Critical patent/CN116368243A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180069281.4A 2020-08-12 2021-08-11 复制应激通路剂组合物和用于治疗癌症的方法 Pending CN116368243A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063064555P 2020-08-12 2020-08-12
US63/064,555 2020-08-12
US202163168120P 2021-03-30 2021-03-30
US63/168,120 2021-03-30
PCT/US2021/045556 WO2022035970A1 (en) 2020-08-12 2021-08-11 Replication stress pathway agent compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
CN116368243A true CN116368243A (zh) 2023-06-30

Family

ID=80247345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180069281.4A Pending CN116368243A (zh) 2020-08-12 2021-08-11 复制应激通路剂组合物和用于治疗癌症的方法

Country Status (11)

Country Link
US (3) US11547711B2 (enExample)
EP (1) EP4196614A4 (enExample)
JP (1) JP2023537600A (enExample)
KR (1) KR20230098134A (enExample)
CN (1) CN116368243A (enExample)
AU (1) AU2021325905A1 (enExample)
BR (1) BR112023002453A2 (enExample)
CA (1) CA3187760A1 (enExample)
MX (1) MX2023001717A (enExample)
TW (1) TW202221118A (enExample)
WO (1) WO2022035970A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116083576A (zh) * 2022-12-07 2023-05-09 上海市临床检验中心 一种基于CRISPR/Cas12a的KRAS热点基因突变检测系统和方法
CN116445411A (zh) * 2023-02-01 2023-07-18 复旦大学附属华山医院 一种小鼠结肠癌索托拉西布耐药细胞株及制备方法与应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
EP4278185A1 (en) * 2021-01-18 2023-11-22 GBG Forschungs GmbH Method for predicting the response to cdk4/6 inhibitor therapy in cancer patients
EP4347582A4 (en) 2021-05-27 2025-05-07 Boundless Bio, Inc. CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用
EP4587026A1 (en) * 2022-09-15 2025-07-23 Recurium IP Holdings, LLC Combinations
EP4770642A2 (en) * 2023-09-01 2026-07-08 Boundless Bio, Inc. Ribonucleotide reductase (rnr) compositions and methods of use
WO2025184572A1 (en) * 2024-03-01 2025-09-04 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS567007A (en) 1979-06-29 1981-01-24 Toshiba Corp Coating film thickness measuring apparatus
WO2018136837A1 (en) * 2017-01-20 2018-07-26 The Jackson Laboratory A method of targeting patient-specific oncogenes in extrachromosomal dna to treat glioblastoma
MX2019012176A (es) * 2017-04-10 2020-02-19 Sierra Oncology Inc Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
US11193164B2 (en) * 2017-05-24 2021-12-07 The Regents Of The University Of California Methods of diagnosing and treating cancer targeting extrachromosomal DNA
AU2018278336A1 (en) * 2017-06-01 2020-01-16 Crt Pioneer Fund Lp Biomarkers and patient selection strategies
US20210047693A1 (en) * 2017-11-15 2021-02-18 The Regents Of The University Of California Methods of treating extrachromosomal dna expressing cancers
JP2021514979A (ja) * 2018-02-26 2021-06-17 シエラ オンコロジー， インコーポレイテッド Ｃｈｋ１阻害剤を含む癌の治療方法
WO2020123530A1 (en) * 2018-12-10 2020-06-18 The Regents Of The University Of California Compositions and methods for modulating transcriptional activity of amplified oncogenes contained on extrachromosomal dna
EP3966323A4 (en) * 2019-05-06 2024-04-24 The Regents Of The University Of Michigan Targeted therapy
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
EP4347582A4 (en) 2021-05-27 2025-05-07 Boundless Bio, Inc. CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF
KR20240101555A (ko) 2021-09-17 2024-07-02 바운드리스 바이오, 인크. 사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도
EP4402134A4 (en) 2021-09-17 2025-10-15 Boundless Bio Inc SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND THEIR USES
US20230272485A1 (en) 2022-02-16 2023-08-31 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116083576A (zh) * 2022-12-07 2023-05-09 上海市临床检验中心 一种基于CRISPR/Cas12a的KRAS热点基因突变检测系统和方法
CN116083576B (zh) * 2022-12-07 2024-01-30 上海市临床检验中心 一种基于CRISPR/Cas12a的KRAS热点基因突变检测系统和方法
CN116445411A (zh) * 2023-02-01 2023-07-18 复旦大学附属华山医院 一种小鼠结肠癌索托拉西布耐药细胞株及制备方法与应用

Also Published As

Publication number Publication date
US20220143022A1 (en) 2022-05-12
CA3187760A1 (en) 2022-02-17
TW202221118A (zh) 2022-06-01
BR112023002453A2 (pt) 2023-05-02
WO2022035970A1 (en) 2022-02-17
US11547711B2 (en) 2023-01-10
US20230248728A1 (en) 2023-08-10
EP4196614A4 (en) 2024-12-18
MX2023001717A (es) 2023-04-13
US11642345B2 (en) 2023-05-09
US12246017B2 (en) 2025-03-11
EP4196614A1 (en) 2023-06-21
AU2021325905A1 (en) 2023-04-13
US20230078903A1 (en) 2023-03-16
JP2023537600A (ja) 2023-09-04
KR20230098134A (ko) 2023-07-03

Similar Documents

Publication Publication Date Title
US11642345B2 (en) Replication stress pathway agent compositions and methods for treating cancer
JP7536320B2 (ja) Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
US20230210852A1 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
Hehlmann How I treat CML blast crisis
US9241941B2 (en) Methods for treatment of lymphomas with mutations in cell cycle genes
Lopez et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
US20230233565A1 (en) A treatment approach involving kif18a inhibition for chromosomally unstable tumors
CN115867669A (zh) 监测kras突变的方法
WO2020056188A1 (en) Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer
Blandin et al. ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma
CN117355306A (zh) 索托拉西布给药方案
US20200248273A1 (en) Treatment of squamous cell carcinoma
Blay et al. Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial
AU2026200456A1 (en) Treatment of canine cancers
US20180057888A1 (en) Kub5/hera as a determinant of sensitivity to dna damage
US12024707B2 (en) Methods and compositions for modulating lncRNAs and methods of treatment based on lncRNA expression
WO2017086332A1 (ja) 間葉系ｋｒａｓ変異型がん治療剤
US11957677B2 (en) Cancer treatment using FGFR inhibitors and PLK1 inhibitors
Shan et al. Efficacy of metformin and verteporfin treatment alone or in combination in a murine head and neck cancer xenograft model
Pender et al. Understanding lung cancer molecular subtypes
Roggero et al. CDK4/6 inhibitors promote PARP1 degradation and act synergistically with PARP inhibitors in non-small cell lung cancer
Roggero Savoini et al. CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
Zhao et al. Lung Cancers
Ma et al. Targeting intrinsic and CAF-mediated signaling by PI3Kα inhibitor CYH33 attenuated metastasis in lung squamous cell carcinoma
Norouzi et al. DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination